Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
ConclusionHCQ administration is safe for a short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.
Source: Europace - Category: Cardiology Source Type: research
More News: Arrhythmia | Cardiology | COVID-19 | Electrocardiogram | Hydroxychloroquine | Intensive Care | Study | Ventricular Arrhythmia